Zacks Research Has Positive View of Humana FY2026 Earnings

Humana Inc. (NYSE:HUM – Free Report) – Analysts at Zacks Research lifted their FY2026 earnings per share (EPS) estimates for Humana in a note issued to investors on Thursday, November 19th. Zacks Research analyst Team now expects that the insurance provider will earn $9.50 per share for the year, up from their previous estimate of $9.05. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Humana’s current full-year earnings is $9.64 per share. Zacks Research also issued estimates for Humana’s Q1 2028 earnings at $11.72 EPS and Q3 2028 earnings at $6.38 EPS.

Humana (NYSE:HUM – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.30. Humana had a net margin of 0.81% and a return on equity of 8.50%. The firm had revenue of $41.16 billion during the quarter, compared to the consensus estimate of $40.87 billion. During the same period last year, the firm posted $3.24 EPS. The firm’s quarterly revenue was up 26.1% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.500- EPS.

A number of other equities analysts also recently weighed in on HUM. Raymond James Financial restated an “outperform” rating on shares of Humana in a report on Friday, November 6th. Sanford C. Bernstein reiterated an “outperform” rating and issued a $515.00 target price on shares of Humana in a research report on Tuesday. TD Cowen upgraded shares of Humana from a “hold” rating to a “buy” rating and raised their price objective for the company from $430.00 to $485.00 in a report on Friday. ThinkEquity started coverage on shares of Humana in a report on Monday, November 16th. They issued a “buy” rating on the stock. Finally, Leerink Partners upgraded Humana from a “market perform” rating to an “outperform” rating and set a $513.00 target price for the company in a research note on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Humana has a consensus rating of “Moderate Buy” and an average target price of $491.74.

Read Our Latest Analysis on Humana

Humana Stock Up 2.6%

NYSE:HUM opened at $389.98 on Friday. The company has a market cap of $46.84 billion, a PE ratio of 37.94, a PEG ratio of 1.87 and a beta of 0.65. The stock has a 50-day simple moving average of $409.49 and a 200 day simple moving average of $322.39. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.65 and a current ratio of 1.65. Humana has a 52-week low of $163.11 and a 52-week high of $462.87.

Institutional Trading of Humana

A number of large investors have recently made changes to their positions in the stock. Defiance ETFs LLC purchased a new position in shares of Humana in the third quarter worth $201,000. DGS Capital Management LLC grew its stake in Humana by 31.8% during the third quarter. DGS Capital Management LLC now owns 849 shares of the insurance provider’s stock valued at $324,000 after acquiring an additional 205 shares in the last quarter. Innovator Capital Management LLC bought a new stake in Humana in the 3rd quarter valued at $2,546,000. Brown Financial Advisors lifted its stake in Humana by 4.8% in the 3rd quarter. Brown Financial Advisors now owns 1,228 shares of the insurance provider’s stock worth $468,000 after purchasing an additional 56 shares in the last quarter. Finally, iSAM Funds UK Ltd purchased a new stake in Humana in the 3rd quarter worth $305,000. 92.38% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Joseph Ventura sold 5,495 shares of the company’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $433.85, for a total value of $2,384,005.75. Following the completion of the transaction, the insider directly owned 21,910 shares in the company, valued at approximately $9,505,653.50. This represents a 20.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.20% of the company’s stock.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be given a $0.8850 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Thursday, December 24th. Humana’s dividend payout ratio (DPR) is 34.44%.

Humana News Summary

These are some of the HUM news items that stood out recently:

  • Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $9.50 from $9.05 and its Q1 2028 estimate to $11.72 from $11.53, while maintaining a “Strong Buy” rating. MarketBeat analyst estimates
  • Positive Sentiment: Morgan Stanley lifted its price target to $475 from $370, though it kept an “Equal Weight” rating. Morgan Stanley price target
  • Negative Sentiment: Zacks Research trimmed its Q3 2028 EPS estimate to $6.38 from $6.58, tempering the positive estimate revisions elsewhere. MarketBeat analyst estimates

About Humana

(Get Free Report)

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

Recommended Stories

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.